Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review

Wu, 2012, Signaling pathways in liver cancer, Liver Tumors, 10.5772/31381 Bangaru, 2020, Review article: new therapeutic interventions for advanced hepatocellular carcinoma, Aliment. Pharmacol. Ther., 51, 78, 10.1111/apt.15573 Xing, 2020, Overexpression of p62/IMP2 can promote cell migration in hepatocellular carcinoma via activation of the wnt/β-catenin pathway, Cancers, 12, 1 Baig, 2019, Current status of nanomaterial-based treatment for hepatocellular carcinoma, Biomed. Pharmacother., 116, 10.1016/j.biopha.2019.108852 Wu, 2020, Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma, Int. J. Biol. Sci., 16, 1551, 10.7150/ijbs.44024 Yang, 2020, KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway, J. Cell. Physiol., 235, 6507, 10.1002/jcp.29444 Vilchez, 2016, Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment, World J. Gastroenterol., 22, 823, 10.3748/wjg.v22.i2.823 Li, 2018, Mefloquine targets β-catenin pathway and thus can play a role in the treatment of liver cancer, Microb. Pathog., 118, 357, 10.1016/j.micpath.2018.03.042 Gedaly, 2014, Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535, PLoS One, 9, 10.1371/journal.pone.0099272 Han, 2020, Expression and prognostic significance of CDK8 and β-catenin in hepatocellular carcinoma, In Vivo, 34, 1387, 10.21873/invivo.11918 Mintz, 2021, The use of nanotechnology to combat liver cancer: progress and perspectives, Biochim. Biophys. Acta Rev. Cancer, 1876, 10.1016/j.bbcan.2021.188621 Annick Buendia, 2000, Genetics of hepatocellular carcinoma, Semin. Cancer Biol., 10, 185, 10.1006/scbi.2000.0319 Min, 2013, Liver-specific and echogenic hyaluronic acid nanoparticles facilitating liver cancer discrimination, Adv. Funct. Mater., 23, 5518, 10.1002/adfm.201301131 Silva, 2020, Challenges and therapeutic opportunities of autophagy in cancer therapy, Cancers, 12, 1, 10.3390/cancers12113461 Ching, 2003, Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma, J. Biol. Chem., 278, 10824, 10.1074/jbc.M208310200 Wu, 2021, Nanotechnology for hepatocellular carcinoma: from surveillance, diagnosis to management, Small, 17, 1 Harris, 2002, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94, 25, 10.1002/cncr.10201 Foerster, 2021, The current landscape of clinical trials for systemic treatment of hcc, Cancers, 13, 10.3390/cancers13081962 Couri, 2019, Goals and targets for personalized therapy for HCC, Hepatol. Int., 13, 125, 10.1007/s12072-018-9919-1 Choi, 2010, Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. Imaging diagnosis and staging of hepatocellular carcinoma, J. Hepatobiliary. Pancreat. Sci., 17, 369, 10.1007/s00534-009-0227-y Eguchi, 2011, Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma, Br. J. Surg., 98, 552, 10.1002/bjs.7393 Margini, 2016, The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment, Liver Int., 36, 317, 10.1111/liv.13031 Liu, 2020, 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma, J. Transl. Med., 18, 1, 10.1186/s12967-020-02462-1 Rahbari, 2011, Hepatocellular carcinoma: current management and perspectives for the future, Ann. Surg., 253, 453, 10.1097/SLA.0b013e31820d944f Kim, 2017, Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy, J. Gastrointest. Oncol., 8, 256, 10.21037/jgo.2016.09.07 Sturm, 2004, Multimodal treatment of hepatocellular carcinoma (HCC), Onkologie, 27, 294 Personeni, 2019, Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date, J. Hepatocell. Carcinoma, 6, 31, 10.2147/JHC.S168953 Reinhardt, 2017, 乳鼠心肌提取 HHS Public Access, Stem Cell Rep., 176, 139 Personeni, 2018, Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications, Drugs Context, 7, 1, 10.7573/dic.212533 Li, 2019, Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway, EBioMedicine, 39, 239, 10.1016/j.ebiom.2018.11.063 Karimkhanloo, 2020, Potential role of miR-214 in β-catenin gene expression within hepatocellular carcinoma, Mol. Biol. Rep., 47, 7429, 10.1007/s11033-020-05798-5 Dahmani, 2011, The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma, Clin. Res. Hepatol. Gastroenterol., 35, 709, 10.1016/j.clinre.2011.05.010 Zhu, 2021, TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates beta-catenin/TCF signalling, J. Cell. Mol. Med., 25, 2356, 10.1111/jcmm.14787 Shin, 2013, Molecular targeted therapy for hepatocellular carcinoma: current and future, World J. Gastroenterol., 19, 6144, 10.3748/wjg.v19.i37.6144 Liu, 2022, Wnt / β -catenin signalling: function, biological mechanisms, and therapeutic opportunities, Signal. Transduct. Target. Ther. MacDonald, 2009, Wnt/β-catenin signaling: components, mechanisms, and diseases, Dev. Cell., 17, 9, 10.1016/j.devcel.2009.06.016 Khalaf, 2018, Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance, J. Hepatocell. Carcinoma, Volume 5, 61, 10.2147/JHC.S156701 Westphal, 2022, Wnt / β ‑ catenin signaling promotes neurogenesis in the diencephalospinal dopaminergic system of embryonic zebrafish, Sci. Rep., 1 H. Carcinoma, T. Aoki, N. Nishida, Clinical Significance of the Duality of Wnt / β -Catenin Signaling, (2022) 1–15. Wang, 2022, CircRNA-IGLL1 / miR-15a / RNF43 axis mediates ammonia-induced autophagy in broilers jejunum via Wnt / β -catenin pathway, Environ. Pollut., 292, 10.1016/j.envpol.2021.118332 Cui, 2003, Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes, J. Gastroenterol. Hepatol., 18, 280, 10.1046/j.1440-1746.2003.02973.x Chen, 2021, Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma, Sci. Rep., 11, 1 R. Yan, H. Zhu, P. Huang, M. Yang, M. Shen, Y. Pan, C. Zhang, Article Liquidambaric Acid Inhibits Wnt / b -Catenin Signaling and Colon Cancer Via Targeting TNF Receptor- Associated Factor 2 ll Liquidambaric Acid Inhibits Wnt / b -Catenin Signaling and Colon Cancer Via Targeting TNF Receptor-associated Factor 2, (2022). 〈https://doi.org/10.1016/j.celrep.2022.110319〉. N. Harada, H. Oshima, M. Katoh, Y. Tamai, M. Oshima, M.M. Taketo, Hepatocarcinogenesis in Mice with ␤ -Catenin and Ha-Ras Gene Mutations, (2004) 48–54. Thompson, 2007, WNT/β-catenin signaling in liver health and disease, Hepatology, 45, 1298, 10.1002/hep.21651 H. Malignancies, Unique Phenotype of Hepatocellular Cancers with, (n.d.) 821–831. 〈https://doi.org/10.1002/hep.22695〉. R.N. Aravalli, C.J. Steer, E.N.K. Cressman, Molecular Mechanisms of Hepatocellular Carcinoma, (2008) 2047–2063. 〈https://doi.org/10.1002/hep.22580〉. Nejak-bowen, 2011, Seminars in cancer biology beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad ଝ, Semin. Cancer Biol., 21, 44, 10.1016/j.semcancer.2010.12.010 C. Ange, Y. Wei, D. Cherqui, E.S. Zafrani, M.A. Buendia, Short Communication Nuclear Accumulation of Mutated ␤ -Catenin in Hepatocellular Carcinoma Is Associated with, 155 (1999) 703–710. 〈https://doi.org/10.1016/S0002–9440(10)65168–1〉. Fan, 2001, Beta catenin mutation and overexpression in hepatocellular carcinoma clinicopathologic and prognostic significance, Cancers, 136 Lachenmayer, 2012, Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib, Clin. Cancer Res., 4997, 10.1158/1078-0432.CCR-11-2322 Hiremath, 2021, The multidimensional role of the Wnt / β ‐ catenin signaling pathway in human malignancies, J. Cell Physiol. Belenguer, 2022, RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state, Nat. Commun., 13, 10.1038/s41467-021-27923-z B.O. Qu, B.R. Liu, Y.A.J.U. Du, J. Chen, Y.A.N.Q.I.U. Cheng, W.E.I. Xu, X.I.N.H. Wang, Wnt / β ‑ catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma, (2014) 1175–1178. 〈https://doi.org/10.3892/ol.2014.1828〉. Baffy, 2021, An engineered mayhem: YAP/TAZ mechanosignaling and hepatocarcinogenesis in NAFLD, Explor. Med., 2, 305 Liu, 2020, Medicine in drug discovery targeting Wnt / β -catenin pathway for drug therapy, Med. Drug Discov., 8, 10.1016/j.medidd.2020.100066 Javanmard, 2020, Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection, Infect. Agent. Cancer, 15, 1, 10.1186/s13027-020-00297-5 K. Taniguchi, L.R. Roberts, I.N. Aderca, X. Dong, C. Qian, L.M. Murphy, D.M. Nagorney, L.J. Burgart, P.C. Roche, D.I. Smith, J.A. Ross, W. Liu, Mutational Spectrum of b -Catenin, AXIN1, and AXIN2 in Hepatocellular Carcinomas and Hepatoblastomas, (2002) 4863–4871. 〈https://doi.org/10.1038/sj.onc.1205591〉. Akasu, 2021, Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma, Sci. Rep., 11, 1, 10.1038/s41598-021-96167-0 Yue, 2021, Sempervirine inhibits proliferation and promotes apoptosis by regulating wnt/β-catenin pathway in human hepatocellular carcinoma, Front. Pharmacol., 12, 1, 10.3389/fphar.2021.806091 A. Bengochea, M.M. De Souza, L. Lefranc, E. Le Roux, O. Galy, I. Chemin, M. Kim, J.R. Wands, C. Trepo, P. Hainaut, J. Scoazec, L. Vitvitski, P. Merle, M. Physiopathology, N. Therapies, A. Thomas, M. Carcinogenesis, B. Lyon-, Common Dysregulation of Wnt / Frizzled Receptor Elements in Human Hepatocellular Carcinoma, (2008) 143–150. 〈https://doi.org/10.1038/sj.bjc.6604422〉. Liu, 2019, FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway, Eur. Rev. Med. Pharmacol. Sci., 23, 8265 Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int. J. Cancer, 127, 2893, 10.1002/ijc.25516 Kim, 2011, Assessment of the treatment response of HCC, Abdom. Imaging, 36, 300, 10.1007/s00261-011-9683-3 Luu, 2004, Wnt / β -catenin signaling pathway as novel cancer drug targets, Expert Opin. Ther. Targets, 653 Jin, 2021, SMG9 serves as an oncogene to promote the tumor progression via EMT and Wnt/β-catenin signaling pathway in hepatocellular carcinoma, Front. Pharmacol., 12, 1, 10.3389/fphar.2021.701454 Foulquier, 2018, WNT signaling in cardiac and vascular disease, Pharmacol. Rev., 68, 10.1124/pr.117.013896 Legoix, 1999, Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity, Oncogene, 18, 4044, 10.1038/sj.onc.1202800 M. Zhang, W. Weng, Q. Zhang, Y. Wu, S. Ni, C. Tan, M. Xu, The lncRNA NEAT1 Activates Wnt / β -Catenin Signaling and Promotes Colorectal Cancer Progression Via Interacting with DDX5, (2018) 1–13. X. Fu, X. Zhu, F. Qin, Y. Zhang, J. Lin, Y. Ding, Z. Yang, Y. Shang, Linc00210 drives Wnt / β -Catenin Signaling Activation and Liver Tumor Progression Through CTNNBIP1-Dependent Manner, (2018) 1–14. Jeong, 2018, Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway, Npj Precis. Oncol., 2, 1 Çalış, 2019, Nanopharmaceuticals as Drug-Delivery Systems, Nanocarriers, Drug Deliv., 133 Vaidya, 2020, Development of inhalable quinacrine loaded bovine serum albumin modi fi ed cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics, Int. J. Pharm., 577, 10.1016/j.ijpharm.2019.118995 Tangutoori, 2014, Repurposing an erstwhile cancer drug : a quantitative and therapeutic evaluation of alternative nanosystems for the delivery of colchicine to solid tumors, Cancer Sci. Ther., 6, 236 Olgen, 2019, Drug repurposing in the development of anticancer agents, Curr. Med. Chem., 5410, 10.2174/0929867325666180713155702 B. Lundström-stadelmann, R. Rufener, A. Hemphill, IJP: Drugs and Drug Resistance Drug Repurposing Applied: Activity of the Anti-malarial Mefloquine Against Echinococcus multilocularis, (2020). 〈https://doi.org/10.1016/j.ijpddr.2020.06.002〉. C. Pérez-plasencia, E. López-urrutia, V. García-castillo, Interplay Between Autophagy and Wnt / β -Catenin Signaling in Cancer : Therapeutic Potential Through Drug Repositioning, 10 (2020) 1–8. 〈https://doi.org/10.3389/fonc.2020.01037〉. Sahu, 2018, Recent progress in the design of hypoxia-specific nano drug delivery systems for cancer therapy, Adv. Ther., 1, 1800026, 10.1002/adtp.201800026 Curumin paper (5).pdf, (n.d.). Khan, 2021, Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling, Phytomedicine, 91, 10.1016/j.phymed.2021.153706 Shao, 2020, LincROR mediates the suppressive effects of curcumin on hepatocellular carcinoma through inactivating Wnt/β-catenin signaling, Front. Pharmacol., 11, 1, 10.3389/fphar.2020.00847 Huang, 2021, Autophagic inhibition of Caveolin-1 by compound Phyllanthus urinaria L. activates ubiquitination and proteasome degradation of β-catenin to suppress metastasis of hepatitis B-associated hepatocellular carcinoma, Front. Pharmacol., 12, 1 Liu, 2007, Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles, Int. J. Cancer, 120, 2527, 10.1002/ijc.22709 Fang, 2020, Stimuli-responsive charge-reversal nano drug delivery system: the promising targeted carriers for tumor therapy, Int. J. Pharm., 575, 10.1016/j.ijpharm.2019.118841 Llovet, 2018, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat. Rev. Clin. Oncol., 15, 599, 10.1038/s41571-018-0073-4 SL, 2016, Cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells, without harming MCF-10A healthy cells, J. Nanomed. Nanotechnol., 07, 10.4172/2157-7439.1000369 Fu, 2022, Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions, Acta Pharm. Sin. B., 12, 532, 10.1016/j.apsb.2021.09.006 Huynh, 2003, Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis, BMC Gastroenterol., 3, 1, 10.1186/1471-230X-3-19 yun Li, 2021, ZEB1 serves an oncogenic role in the tumourigenesis of HCC by promoting cell proliferation, migration, and inhibiting apoptosis via Wnt/β-catenin signaling pathway, Acta Pharmacol. Sin., 42, 1676, 10.1038/s41401-020-00575-3 Piktel, 2016, Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy, J. Nanobiotechnol., 14, 1, 10.1186/s12951-016-0193-x Taghizadeh, 2019, Gold nanoparticles application in liver cancer, Photodiagnosis Photodyn. Ther., 25, 389, 10.1016/j.pdpdt.2019.01.027 Guan, 2017, From detection to resection: photoacoustic tomography and surgery guidance with Indocyanine Green loaded gold nanorod@liposome core-shell nanoparticles in liver cancer, Bioconjug. Chem., 28, 1221, 10.1021/acs.bioconjchem.7b00065 T. Barupal, Y. Sompura, S. Sharma, Significant Role of Nanotechnology in Cancer and Molecular Genetics: an Overview Significant role of Nanotechnology in Cancer and Molecular Genetics: an Overview, (2022). Martini, 2014, PI3K/AKT signaling pathway and cancer: an updated review, Ann. Med., 46, 372, 10.3109/07853890.2014.912836 Fan, 2020, Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo, Cell Death Dis., 11, 10.1038/s41419-020-2317-3 Assad Kahn, 2016, The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKC δ‐dependent inhibition of the AKT pathway, EMBO Mol. Med., 8, 511, 10.15252/emmm.201505421 Zaganjor, 2011, Function and modulation of MAPK pathway, Tocris Biosci. Cient. Rev. Ser., 35, 1 Han, 2021, Verapamil inhibits early acute liver failure through suppressing the NLRP3 inflammasome pathway, J. Cell. Mol. Med., 25, 5963, 10.1111/jcmm.16357 yue Tang, 2020, Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma, J. Integr. Med., 18, 196, 10.1016/j.joim.2020.02.002 Espinoza, 2020, The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity, Cell Death Differ., 27, 773, 10.1038/s41418-019-0387-5 Lee, 2006, A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat. Med., 12, 410, 10.1038/nm1377 Wang, 2009, Advances of cancer therapy by nanotechnology, Cancer Res. Treat., 41, 1, 10.4143/crt.2009.41.1.1 Thomas, 2005, Opportunities for targeted therapies in hepatocellular carcinoma, J. Clin. Oncol., 23, 8093, 10.1200/JCO.2004.00.1537 Blagodatski, 2014, Targeting the Wnt pathways for therapies, Mol. Cell. Ther., 2, 28, 10.1186/2052-8426-2-28 Deng, 2022, Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles, J. Nanobiotechnol., 20, 1, 10.1186/s12951-022-01378-w Patel, 2021, Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery, New J. Chem., 45, 5291, 10.1039/D0NJ04134C Chen, 2016, Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates, J. Pharm. Biomed. Anal., 117, 304, 10.1016/j.jpba.2015.09.015 Li, 2022, A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy, Eur. J. Med. Chem., 228, 10.1016/j.ejmech.2021.114037 Li, 2016, An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates, MAbs, 8, 698, 10.1080/19420862.2016.1151590 Independent, 1978, Drug and therapeutics bulletin index, Drug Ther. Bull., 16, 76, 10.1136/dtb.16.19.76 Vogl, 2010, Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer, Eur. Radiol., 20, 173, 10.1007/s00330-009-1525-0 Liu, 2021, Itraconazole therapy for infant hemangioma: two case reports, World J. Clin. Cases., 9, 8579, 10.12998/wjcc.v9.i28.8579 Wang, 2020, Lenalidomide enhances CAR-T cell activity against solid tumor cells, Cell Transpl., 29, 1, 10.1177/0963689720920825 Guo, 2018, Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy, Nat. Commun., 9, 10.1038/s41467-018-05764-7 Kumbhar, 2022, Inhalation delivery of repurposed drugs for lung cancer: approaches, benefits and challenges, J. Control. Release, 341, 1, 10.1016/j.jconrel.2021.11.015 Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734 Chen, 2020, Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy, Clin. Transl. Med., 10, 1, 10.1002/ctm2.219 Ma, 2020, Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism, J. Bioenerg. Biomembr., 52, 123, 10.1007/s10863-020-09824-w Chen, 2020, Tumor-specific nanomedicine: via sequential catalytic reactions for accurate tumor therapy, J. Mater. Chem. B, 8, 6857, 10.1039/C9TB02812A Zheng, 2020, Recent advances in plant polysaccharide-mediated nano drug delivery systems, Int. J. Biol. Macromol., 165, 2668, 10.1016/j.ijbiomac.2020.10.173 Kozani, 2021, AS1411-functionalized delivery nanosystems for targeted cancer therapy, Explor. Med., 2, 146 Fausto, 2003, The role of hepatocytes and oval cells in liver regeneration and repopulation, Mech. Dev., 120, 117, 10.1016/S0925-4773(02)00338-6 Gonciar, 2022, Nanoparticles targeting the molecular pathways of heart remodeling and regeneration, Pharmaceutics, 1 Misra, 2010, Cancer nanotechnology: application of nanotechnology in cancer therapy, Drug Discov. Today, 15, 842, 10.1016/j.drudis.2010.08.006 Anwanwan, 2020, Challenges in liver cancer and possible treatment approaches, Biochim. Biophys. Acta Rev. Cancer, 1873, 10.1016/j.bbcan.2019.188314 Nygårdas, 2002, Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis, Clin. Exp. Immunol., 128, 245, 10.1046/j.1365-2249.2002.01855.x Pandurangan, 2015, Gallic acid attenuates dextran sulfate sodium-induced experimental colitis in BALB/c mice, Drug Des. Dev. Ther., 9, 3923, 10.2147/DDDT.S86345 Salimi, 2020, Treatment of breast cancer-bearing balb/c mice with magnetic hyperthermia using dendrimer functionalized iron-oxide nanoparticles, Nanomaterials, 10, 1, 10.3390/nano10112310 Guo, 2014, Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model, Appl. Microbiol. Biotechnol., 98, 3495, 10.1007/s00253-013-5408-6 Farshi, 2017, Evaluation of antioxidant activity and cytotoxicity of cumin seed oil nanoemulsion stabilized by sodium caseinate- guar gum, Tabriz Univ. Med. Sci., 23, 293 Yang, 2020, Small GTPase RAB6 de fi ciency promotes alveolar progenitor cell renewal and attenuates PM2. 5- induced lung injury and fi brosis, Cell Death Dis., 10.1038/s41419-020-03027-2 Qin, 2022, Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin, BMC Cancer, 22, 1, 10.1186/s12885-022-09684-0